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S UMMA R Y
S E T T I NG : We conducted a qualitative exploration into
the palatability and acceptability of a novel fixed-dose
combination (FDC) anti-tuberculosis drug. This study
was nested in the SHINE (Shorter treatment for minimal
TB in children) trial, which compares the safety and
efficacy of treating non-severe drug-susceptible tubercu-
losis (TB) with a 6 vs. 4 months anti-tuberculosis
regimen in children aged 0–16 years. Participants were
recruited in Cape Town, South Africa.
OB J E C T I V E : To describe the palatability and accept-
ability of a FDC of rifampicin, isoniazid and pyrazin-
amide among South African children and their
caregivers in the SHINE trial.
METHODS : We conducted 20 clinic observations of
treatment administration, during which we conducted
16 semi-structured interviews with children and their
caregivers. Data were organised thematically to report on
experiences with administering and ingesting the FDC.
R E SU LT S : Children and caregivers’ experiences varied
from delight to disgust. In general, participants said that
the FDC compared favourably to other formulations.
Pragmatic challenges such as dissolving the FDC and the
time required to administer the FDC impeded caregivers’
ability to integrate treatment into their daily routines.
Drug manipulation was common among caregivers to
improve TB treatment administration.
CONC LU S I ON : This novel FDC appears acceptable for
children, albeit with practical challenges to administra-
tion. Scale-up of FDC use should include supplementary
intervention components to support caregivers.
K E Y WORD S : TB; paediatric; acceptability; palatabili-
ty, fixed-dose combination formulations
ADMINISTERING MEDICATION to children can
be problematic and challenging for both caregivers
and health workers.1,2 Anti-tuberculosis treatment
(ATT) for children is particularly difficult because
regimens consist of multiple drugs given daily over a
long period, typically 6 months, for drug-susceptible
TB.3 Furthermore, research aimed at optimising ATT
regimens and the development of anti-tuberculosis
drugs has largely excluded children and the develop-
ment of child-friendly formulations. ATT regimens
and formulations for children are therefore often
extrapolated from adult data.4 Extrapolations of this
kind do not always result in optimal drug doses and
child-friendly formulations. This can have an impact
on treatment efficacy, increase the likelihood of
toxicity, pill burden and costs to health services and
families.5,6 Fixed-dose combination (FDC) formula-
tions were designed to overcome some of these issues
by including fixed ratios of multiple drugs in a single
pill, and thus simplifying dosing regimens.7
FDCs offer several advantages, including a reduc-
tion in the chance of prescription errors due to the use
of ‘weight-band’ dosing tablets, a reduction in the pill
burden and a reduced likelihood of selective non-
adherence.8 In 2014, the World Health Organization
published revised recommendations for drug dosing
in paediatric ATT regimens.9 The ratios of drugs in
pre-existing FDCs were thus no longer optimal. To
address these changes in treatment recommendations,
new child-friendly FDCs that comply with the 2014
WHO guidelines, were developed.10 These FDCs are
already being successfully implemented as part of
national paediatric TB treatment programmes using
simplified weight-band dosing in several countries
across the world, including in some countries in
Africa.1
As with other drugs designed for use in children,
the new FDC is dispersible and has undergone
significant taste-masking to increase ease of admin-
istration.11–13 Dispersible tablets offer the familiarity
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of administering liquid formulations to children,
promising greater ease of administration, and poten-
tially, improving adherence.14,15
Optimal implementation of FDCs requires the
evaluation of their palatability and acceptability in
the context of children’s everyday lives, particularly
with reference to caregivers and familial con-
texts.14,16 This includes evaluating the practical
aspects of administration, the volume of medicine
given and whether or not medication was mixed with
food. Palatability is defined as ‘‘the organoleptic
properties which includes smell, taste, aftertaste, dose
volume or size and texture (mouthfeel)’’, and is an
important consideration for the overall acceptability
among paediatric populations.17–19 Recent studies
suggest that taste preferences may vary by age and
between cultures and different settings, highlighting
the need to show greater sensitivity to the immediate
needs of local populations.19–21 Conducting palat-
ability and acceptability evaluations in the popula-
tions for which the treatment is being developed is a
crucial step in this process.20
We present the experiences of the first children and
their caregivers to use the FDC in the SHINE (Shorter
treatment for minimal TB in children) trial (ISRCTN
63579542) in a high TB burden setting.13 We suggest
lessons learnt for optimising the administration of the
FDC.
METHODS
Setting
The study was conducted in Cape Town, South
Africa. All children included in this study were
enrolled in the SHINE trial and had been recruited
from Tygerberg Hospital (a tertiary referral hospital),
Cape Town, South Africa, or the surrounding clinics.
Cape Town has a high burden of paediatric TB, with
children aged,15 years constituting 13% of the total
TB cases notified, and with approximately 10–15%
of children with confirmed TB being HIV-infected.22
Study design
SHINE is a randomised, open-label, non-inferiority
trial comparing the safety and efficacy of a 6- vs. 4-
month ATT regimen using the WHO-recommended
FDC in 1200 HIV-infected and non-infected children
in South Africa, Zambia, Uganda and India.23
Children aged 0–16 years, weighing 3 kg, and with
symptomatic non-severe TB, regardless of HIV status,
were eligible to participate.
Children were randomised to receive either 4 or 6
months of ATT. Participants weighing ,25 kg
received ATT with the WHO-recommended paediat-
ric FDC, while those weighing 25 kg received the
non-dispersible adult formulation FDC. The paediat-
ric FDC for the intensive phase of anti-tuberculosis
treatment is a dispersible tablet containing three
drugs: isoniazid (H) 50 mgþ rifampicin (R) 75 mgþ
pyrazinamide (Z) 150 mg. Ethambutol was added as
a separate tablet during the intensive phase if
indicated, which in South Africa was only added in
case of HIV-infected children. For the continuation
phase, a two-drug FDC dispersible tablet containing
H 50 mgþR 75 mg was provided. Each FDC tablet is
approximately 100 mm x 50 mm in diameter and can
be dissolved in as little as 5 ml of water.
Between September and December 2016, 28
participants were enrolled into the SHINE trial in
Cape Town. During this initial trial recruitment
phase, we conducted an exploratory sub-study on
palatability and acceptability to describe patients’
and caregivers’ early experiences of the FDCs in
South Africa.
Sampling, recruitment and data collection
We conducted 20 days of clinic observation consisting
of between one and four participants per observation
day. Observations included some SHINE trial partic-
ipants’ first experience of the FDC at enrolment into
the trial (often administered by a member of the trial
team), as well as observations at follow-up visits with
participants who had experienced 2, 4 and 8 weeks of
home administration of the FDC. Participants were
recruited to this sub-study during clinic observation
days and were invited to participate in an interview at
a convenient time and place. We sampled purposively
to include participants with different familial experi-
ence of TB treatment. We continued data collection
until we reached saturation in the experiences
reported by participants. At each of the follow-up
visits, we observed caregivers administering and
participants ingesting the FDC. This allowed us to
explore their adaptation to the treatment and
differences in how they experienced palatability over
time. We captured field notes recording these
observations and completed semi-structured debrief-
ing documents after data collection. All data were
collected by experienced graduate sociobehavioural
science researchers, led by DWand supervised by GH.
We conducted 14 semi-structured interviews with
participants and caregivers at the clinic facility, and
two semi-structured follow-up interviews at partici-
pants’ homes. Although we did not formally inter-
view any health workers, we had numerous informal
conversations with health workers before, during and
after observation days. In total, we spoke to 14
caregivers and children. In all cases, caregivers were
women, usually with one child on treatment and
children were often 0–5-years-old, with some 6–10-
years-old. Interviews were conducted in Xhosa,
Afrikaans or English using a semi-structured inter-
view schedule. Discussions in these interviews fo-
cussed on the acceptability (including palatability) of
the FDC, and any challenges to adherence for both
participants and their caregivers. Specifically, we
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asked participants and their caregivers about 1)
experiences of the FDC’s palatability, 2) experiences
of the FDC compared to any other experiences of
ATT in their family, and 3) practical use of the FDC in
the household context.
Data analysis
Data analysis was an iterative process focussing on
interactions between health workers, children, care-
givers and researchers. After every observation and
interview, the lead social scientist (DW) completed a
structured reflexivity document. This document
focusses specifically on health worker/participant/
caregiver’s understanding and use of the FDC, and its
integration into everyday practices and processes
(both at home and in the clinic).
All interviews were transcribed verbatim in Xhosa
or Afrikaans, and then translated to English. A
deductive thematic analytic approach was used to
identify instances where caregivers and/or children
spoke about their experience of administering and
tasting the FDC.24 We first read through all interview
transcripts and field notes to identify initial codes
with a particular focus on palatability. Thereafter,
codes were organised into themes. Objectives-based
categories were refined through repeated analysis and
re-reading of the data set to verify that interpretations
fit the data. The analysis process and themes were
cross-checked by the first, second and last authors to
promote analytic reliability. Findings were member-
checked with participants and health workers at
subsequent interactions.
Ethics statement and details of informed consent
The SHINE trial and sub-studies, including this
nested palatability and acceptability evaluation,
were approved by the Health Research Ethics
Committee at Stellenbosch University Tygerberg,
(M14/09/044), and by the Medicines Control
Council of South Africa (#20150316), now called
the South African Health Products Regulatory
Authority (SAHPRA; Pretoria, South Africa). The
trial, including this evaluation, is registered on the
ISRCTN database (ISRCTN63579542). All adult
participants (caregivers and health workers) ob-
served and interviewed as part of the palatability and
acceptability assessment provided written informed
consent prior to participation. Caregivers’ informed
consent included their consent that the child TB
patient in their care be included in observations and
interview discussions.
RESULTS
Children and caregivers’ experiences of the FDC’s
palatability
The majority of participants reported that the FDC
was palatable, although there was some variability
in responses. For some participants, the FDC was
pleasant enough to be likened to a ‘treat’ for their
child. For example, one mother spoke about how her
6-year-old daughter drank the treatment as if it were
a ‘cool drink’ and said that when her daughter
finished the course ‘‘she would see there’s no more
boxes [of treatment]’’ and ‘‘ask every day, ‘Mammie,
where are my pills?’’’.
However, most participants reported the FDC was
still recognisably medicinal; for example, the mother
of another 6-year-old girl explained that the FDC’s
appearance when dissolved, belied its taste. Both
mother and daughter complained that the FDC was
bitter, comparing it to a traditional aloe-based
medicine (interview, 26 September 2016):
Yes, it’s like ukrakrayo because it’s bitter. But now
because they are orange, I thought it was like Drink
o’pop (powder-based drink concentrate). But when I
tasted just a little like this [illustrates by bringing her
little finger up to mouth]. I can’t taste the bitterness [it
was not immediately unpalatable to me]. But then
when I ask my daughter, she says it’s bitter, so I
figured it probably is, because she eats it all the time
[she knows what it tastes like more than I do].
(Mother of 6-year-old girl)
The excerpt illustrates that before the mother
tasted the FDC she thought it would be pleasant,
because of its colour. However, both mother and
daughter (patient) were unpleasantly surprised that
the FDC remains a medicine that tastes somewhat
bitter.
In some instances of ingestion, children would
reject administration outright. At these times, chil-
dren appeared not to be responding to the FDC in
isolation, but rather to their whole treatment
experience and situational cues specific to that
administration, for example, being tired. At these
times, caregivers and health workers used a variety of
techniques to overcome this response and encourage
ingestion. Children would sometimes be willing to
ingest the FDC with sufficient positive reinforcement
of compliance—for example, being given high fives
from caregivers and health workers for every sip
swallowed. When ingestion met with a lot of
resistance from the patient, caregivers often resorted
to negotiation—for example, the mother mentioned
above told her 6-year-old daughter ‘‘if you are a good
girl and take your medicine then you can have a
yoghurt’’. However, in some cases, caregivers needed
to use physical compulsion, restraining the child
while forcing them to swallow the treatment. For one
mother, this pattern of using physical restraint
became the norm for ensuring administration for
her 2-year-old daughter—often asking the girl’s aunt
to assist her while she compelled the child to ingest
her treatment (interview, 13 October 2016a).
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Children and caregivers’ comparisons to other anti-
tuberculosis treatments
Despite the diverse reactions to the FDC’s palatabil-
ity, our findings suggest that the FDC compares
favourably to the TB treatment caregivers have seen
other people in their family use. An 8-year-old boy’s
caregiver compared the FDC regimen to her grand-
father’s ATT regimen, saying (interview, 08 Septem-
ber 2016):
Caregiver of 8-year-old boy: What can I say
[laughing] those ones [the grandfathers’ treatment
regimen] would be difficult for the child.
Researcher: They would be difficult?
Caregiver of 8-year-old boy: Yes [laughs]
Researcher: Why? Why would [the] grandfathers
ones [treatment regimen] be too difficult?
Caregiver of 8-year-old boy: They [the tablets] are a
lot.
The caregiver suggests that children would struggle
to consume many pills at a time. In addition to
reducing the perceived pill burden, the FDC proved to
have various other characteristics which eased
administration. For example, its dispersibility in
small volumes of water, relatively small size and ease
of application to weight-bands—since almost all
children received one or more whole, not partial
tablets. One of the caregivers compared the FDC to
her older niece’s treatment regimen saying that, her
niece’s treatment ‘‘was big, it was a big pill not like
hers [pointing to the FDC]’’. She went on to cite the
dispersible nature of the treatment as one of the
reasons why she finds it a more acceptable regimen: ‘‘I
think this one [the FDC] that dissolves in water is
better for her [indicating to her daughter] and for me
[as caregiver supporting her ingestion]’’. Not only
was the FDC easy to prepare and to administer, but its
dispersibility also acted as a safeguard against spitting
out the medicine.
Unlike other TB drugs, the FDC’s dispersibility also
gave caregivers the freedom to use various imple-
ments to administer treatment, including a spoon,
small cup or syringe. As a result, caregivers were able
to use very small volumes (as little as 5 ml) of water to
prepare the FDC for administration. In the excerpt
below, the caregiver illustrates how the FDC’s small
volume and adaptable administration allowed her to
use a syringe to administer the treatment to her 20-
month-old boy (interview, 19 September 2016b):
Mother of 20 month-old-boy: For that medication
[the FDC], I took the pill I put in the cup, and then I
put water and, then it melted. I take a syringe and
then I give it [to him in the] syringe.
Researcher: And how many pills is he taking?
Mother of 20 month-old-boy: It’s only one but now
they say they gonna change it, it’s gonna be two now.
Researcher: And then you use the syringe, do you
have to hold him, is it difficult or?
Mother of 20 month-old-boy: I must hold him and
then I give.
Researcher: Does he try to push it [the syringe] away
with his hands?
Mother of 20 month-old-boy: No, he doesn’t push it
away.
While it is easier for children to refuse the spoon/
cup, a syringe when placed inside the mouth induces
the swallowing reflex and thereby ensures maximum
ingestion. However, there are some concerns about
the feasibility of cleaning the syringe sufficiently
between administrations.
Children and caregiver’s practical use of the FDC in the
household context
Caregivers still experience a number of challenges in
administering the FDC in their homes and adopt
innovative strategies to overcome these challenges.
These challenges are also true to varying degrees for
non-FDC formulations and other regimens. It should
be noted that although the FDC is comparatively
more palatable and its dispersibility improves ease of
administration, this is not a panacea for TB treatment
adherence among paediatric patients in South Africa.
Some of the ongoing challenges suggest that overall
acceptability of the FDC is not ideal.
Some caregivers combined the FDC with food—
frequently yoghurt or porridge. Several of the
caregivers used yoghurt to bribe their child to take
the treatment. Although health workers’ instructions
were to refrain from administering the treatment with
dairy products for fear of influencing the formula-
tion’s absorption, some caregivers insisted that the
treatment be administered in or with yoghurt. For
example, the mother of a 6-year-old girl said
(interview, 26 September 2016) ‘‘it can be rather put
in yoghurt, right? It could be better’’. However, other
caregivers said that their child preferred to swallow
the tablet whole. This was particularly the case for
older children who would otherwise complain about
the FDC’s taste—for example, the caregiver of a 10-
year-old boy said, ‘‘it used to make him nauseous at
that time [when he drank it dispersed in water]’’
(interview, 29 September 2016).
Another challenge revolved around the primary
caregiver’s ability to integrate timely administration
of the FDC into everyday life. Caregivers often set
aside 15–30 minutes each morning to administer
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treatment. One mother, whose 9-month-old boy
resisted the treatment, described her experience with
the treatment as follows (interview, 12 September
2016):
Mother of 9-month-old boy: I am just practicing now
just before I go to work around half past five [in the
morning] I must start dissolving them [the FDC] and
then I leave them and I prepare everything else [like
breakfast and getting dressed] and then at least by six
o’clock I give it to him.
Another mother described how she too struggled to
incorporate the treatment into her everyday schedule
saying that the FDC stains clothing. To comply with
the recommended morning administration, she woke
up at 04:00 (am), undressed herself, undressed her
daughter, and then spent 30–45 minutes coaxing her
daughter to take the treatment before washing up and
going to work. She undressed to avert the financial
and time costs of having to clean and change both her
own and her child’s clothing each morning, should
her daughter spit up the FDC. Children living with
HIV would take their ART in the evening. Some
caregivers misinterpreted the recommendation to
administer TB treatment in the morning as a non-
negotiable directive from health workers resulting in
two burdensome drug administration events per day.
Other caregivers decided to forego the recommended
morning administration, relying rather on daily
cues—such as eating dinner together as a family, or
watching daily soap operas—to remind them to
administer the FDC.
Caregivers also cited their child’s physical and
emotional state as hindering or helping administra-
tion. Other challenges included psychosocial factors
(such as having to take time off work to attend clinic
meetings), stigma (particularly for children going to
school) and lack of knowledge/education or misper-
ceptions about adverse effects, affected treatment
administration and adherence. While none of our
participants struggled to access safe, clean water, this
may not be the case in other under-resourced
countries.
DISCUSSION
The FDC is part of a wave of new treatment regimens
created to be more palatable and child-friendly,
aiming to bring down barriers to long-term adherence
and reduce mortality and the likelihood of drug
resistance.25–27 Children and caregivers’ experiences
of the FDC’s palatability ranged from delight to
disgust. Because of its appealing colour and familiar
presentation in soluble form, caregivers and children
were surprised to find that the FDC was more bitter
than expected. Caregivers were innovative in over-
coming the challenges posed by poor palatability
through positive reinforcement, bribery and, in some
cases, physical compulsion. Additional strategies
included administering the FDC in solid pill form
rather than dissolving it or administering the FDC in/
with solids and fluids (e.g., water, yoghurt, porridge,
etc.). Different strategies appeared to work for
different children of different ages, as caregivers
managed incorporating the FDC into their everyday
routine—which sometimes resulted in significant
time and money costs.
Acceptability has previously been defined as the
‘‘overall ability of the patient and caregiver (defined
as ‘‘user’’) to use a medicinal product as intended (or
authorised)’’.15 More recently, Simon Bryson has
endorsed a ‘patient-centred medicine’ definition of
acceptability, which is medicine that ‘‘the patient will
deem acceptable, to the extent that they will willingly
participate in taking the medication on a routine
basis, in chronic treatment’’.28 Bryson goes on to
explain that medicine should be considered ‘admin-
istration-friendly’, ‘‘which may be defined as one
whose dose is easy to measure, and administer
without modification’’.28 While we believe our
description of the ease with which caregivers and
patients can prepare and administer the FDC meet
Bryson’s ‘administration-friendly’ criteria; both defi-
nitions of ‘acceptability’ belie the complexity of
everyday life and the myriad pragmatic, financial
and social challenges that caregivers face during the
treatment process for children affected by TB.
Definitions of ‘acceptability’ for anti-tuberculosis
drugs or regimens may differ in different sociocultur-
al contexts and should therefore be investigated more
systematically in diverse settings.29,30 Despite being
given instructions on how to administer treatment,
we observed that drug manipulation is common
practice among caregivers who adapt and adopt
different strategies to improve TB treatment admin-
istration to children. Further research is needed to
confirm the pharmacokinetic implications of these
real-life approaches to administration of anti-tuber-
culosis drugs (given with yoghurt or over a couple of
hours). We recommend that drug designers better
understand the practical issues in the administration
of treatment in children before formulations are
developed and taken to market—including accept-
ability for children and caregivers.
The limitations of this study are that the sample
size was small and that data collection to the point of
saturation across all experiences was unfeasible; these
restrain us from being able to describe these
complexities in more detail. We were also unable to
conduct formal comparisons between childrens’ prior
experiences of ATTwith the FDC used in the SHINE
trial as none of the children included had received TB
treatment before. Longer-term, more indepth, quan-
titative and qualitative research is needed to uncover
the many factors involved in making treatment
acceptable.
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Recent research suggests that health workers should
work with caregivers to establish tailored ingestion
support processes that simultaneously ease adminis-
tration and preserve drug bioavailability.31 We further
recommend that scale-up of FDC use includes
supplementary structured initial and ongoing educa-
tion and adherence support to improve caregivers’
ability to effectively manage administration.
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R E´ S U M E´
C O N T E X T E : Nous avons re´alise´ une exploration
qualitative de la palatabilite´ et de l’acceptabilite´ d’une
nouvelle combinaison a` doses fixes (FDC) de
me´dicaments antituberculeux. Re´alise´e au sein de
l’essai SHINE (Shorter treatment for minimal TB in
children), qui compare la se´curite´ et l’efficacite´ du
traitement d’une tuberculose (TB) pharmacosensible
non grave avec un protocole antituberculeux de 6 mois
au lieu de 4 mois chez des enfants aˆge´s de 0–16 ans. Les
participants ont e´te´ recrute´s au Cap, Afrique du Sud.
OB J E C T I F : De´crire la palatabilite´ et l’acceptabilite´
d’une FDC de rifampicine, d’isoniazide et de
pyrazinamide parmi des enfants Sud-Africains et leurs
responsables dans l’essai SHINE.
M E´ T H O D E : Nous avons re´alise´ 20 observations
cliniques de l’administration du traitement, au cours
desquelles nous avons conduit 16 entretiens semi
structure´s avec les enfants et leurs responsables. Les
donne´es ont e´te´ organise´es par the`me afin de rapporter
les expe´riences des patients en matie`re d’administration
et d’ingestion des FDC.
R E´ S U LTAT S : Les expe´riences des enfants et de leurs
responsables ont varie´ de l’enchantement au de´gouˆt. En
ge´ne´ral, les participants ont de´clare´ que les FDC se
comparaient avantageusement aux autres formulations.
Ne´anmoins, des proble`mes pratiques comme la
dissolution des FDC et le temps requis pour les
administrer a entrave´ la possibilite´ d’inte´grer le
traitement dans la routine quotidienne. La
manipulation des me´dicaments a e´te´ fre´quemment faite
par les responsables afin d’ame´liorer l’administration du
traitement de TB.
CONC LU S I ON : Cette nouvelle FDC semble acceptable
pour les enfants, malgre´ des proble`mes pratiques en
matie`re d’administration. L’expansion du recours aux
FDC devrait inclure des e´le´ments supple´mentaires
d’intervention afin de soutenir les responsables.
R E S UM E N
MA R C O D E R E F E R E N C I A: Se llevo´ a cabo una
evaluacio´n cualitativa del sabor y la aceptabilidad de
una nueva asociacio´n de dosis fijas (FDC) de fa´rmacos
antituberculosos. Fue este un estudio anidado en el
ensayo SHINE (Shorter treatment for minimal TB in
children), que comparaba la seguridad y la eficacia de
tratar casos de tuberculosis (TB) no grave,
normosensible, con esquemas de 6 meses y 4 meses en
los nin˜os de 0 a 16 an˜os. Los participantes se ingresaron
al estudio en Ciudad del Cabo en Sura´frica.
O B J E T I V O S: Describir la calidad del sabor y la
aceptabilidad de una FDC de rifampicina, isoniazida y
pirazinamida en los nin˜os surafricanos y sus cuidadores
que participaban en el ensayo clı´nico SHINE.
M E´ TODO: Se practicaron 20 observaciones clı´nicas de la
administracio´n del tratamiento, durante las cuales se
realizaron 16 entrevistas semiestructuradas a los nin˜os y
sus cuidadores. Los datos se organizaron por temas, a fin
de comunicar las experiencias en la administracio´n y la
ingestio´n de la FDC.
R E S U LTADO S: Las experiencias de los nin˜os y los
cuidadores oscilaron entre el agrado y la repulsio´n. En
general, los participantes afirmaron que la nueva
formulacio´n es al menos tan buena como las otras.
Algunas dificultades pra´cticas como la disolucio´n de la
FDC y el tiempo necesario para administrarla
obstaculizaron la capacidad de los cuidadores para
integrar el tratamiento en sus rutinas cotidianas. Con
frecuencia los cuidadores manipulaban el fa´rmaco con el
fin de mejorar la administracio´n del tratamiento
antituberculoso.
CONC LU S I O´ N: Esta nueva FDC parece aceptable para
los nin˜os, aunque persisten algunas dificultades pra´cticas
de administracio´n. Al ampliar la escala de utilizacio´n de
la FDC es necesario incorporar a la intervencio´n
componentes adicionales que ayuden a los cuidadores.
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